Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA-Reference-Cited by-同舟云学术

Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA

Published:2023-10-13 Issue: Volume: Page:
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Wada Keiko¹,Zhang Jingchuan²,Lee Inyoung¹^ORCID,Wang Yi¹,Near Aimee¹^ORCID,Prabhu Vimalanand S³^ORCID

Affiliation:

1. Real World Solutions, IQVIA Inc., Durham, NC 27703, USA

2. Worldwide Real World Evidence (WW RWE), Eisai Inc., Nutley, NJ 07110, USA

3. Center for Observational and Real World Evidence(CORE), MRL, Merck & Co., Inc., Rahway, NJ 07065, USA

Abstract

Aim: Describe treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy (lenva+pembro) among endometrial cancer (EC) patients in US clinical practice. Materials & methods: Retrospective cohort study among adults with EC initiating lenva+pembro in second line (2L) or third line and later [≥3L] between 17 September 2019 and 30 June 2021. Results: 110 patients initiated lenva+pembro in 2L and 135 patients in ≥3L. Majority of patients initiated lenva+pembro at label-recommended starting doses/interval. Less than half changed lenvatinib dose over time. At median follow-up of 7.3 and 8.7 months, median (95% CI) duration of therapy was 5.1 (4.7–6.1) and 5.8 (4.2–7.3) months for patients in 2L and ≥3L, respectively. Conclusion: Lenva+pembro was mostly initiated at label-recommended dose.

Funder

Merck Sharp and Dohme

Eisai Inc.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2023-0058

Reference18 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. American Cancer Society. Cancer Facts & Figures 2022. www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html (Accessed 15 December 2022).

3. American Cancer Society. Survival Rates for Endometrial Cancer. www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates (Accessed 29 April 2022).

4. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States

5. U.S. Food and Drug Administration (FDA). NDA 206947/S-011 Accelerated Approval. www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/206947Orig1s011ltr.pdf (Accessed 14 April 2022).